Literature DB >> 28088657

Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.

Anna Spreafico1, Linda Coate1, Rihong Zhai2, Wei Xu1, Zheng-Fei Chen1, Zhuo Chen1, Devalben Patel1, Brandon Tse1, M Catherine Brown1, Rebecca S Heist3, Lorin Dodbiba1, Jennifer Teichman1, Matthew Kulke4, Li Su2, Lawson Eng1, Jennifer Knox1, Rebecca Wong1, Gail E Darling1, David C Christiani2, Geoffrey Liu5.   

Abstract

BACKGROUND: Smoking and obesity are esophageal adenocarcinoma (EAC) risk factors. However, the same risk factors may also affect biological aggressiveness and cancer outcomes. Our study evaluated the combined effects of early-adulthood obesity and cumulative smoking on the EAC survival. PATIENTS AND METHODS: In two EAC cohorts, Toronto (TO; N=235) and Boston (BO; N=329), associations between early adulthood body mass index (EA-BMI), BMI at 1year prior to diagnosis (BMI-1), and smoking with overall survival (OS) were assessed using Cox proportional hazard models, adjusted for relevant covariates.
RESULTS: Both cohorts were predominantly Caucasian (89%), male (88%), ever-smokers (73%) with locally advanced/metastatic EAC (78%), and good ECOG performance status (90%); median packyears was 34; median EA-BMI, 24; median BMI-1, 25. No relationships with survival were found with BMI-1. For smoking and EA-BMI, TO, BO, and combined TO-BO analyses showed similar associations: smoking conferred worse OS in the combined TO-BO cohort, with adjusted hazard ratios (aHR) of 1.22 (95%CI: 1.15-1.43;p<0.0001) for each 20 pack-year increase. Likewise, EA-BMI ≥25 was associated with worse OS (EA-BMI of 25-<30, aHR=1.84,95%CI: 1.37-2.48; and EA-BMI>30, aHR=2.78, 95%CI: 1.94-3.99). Risk of death was also increased in remotely underweight patients with EA-BMI<18.5 (aHR=2.03,95%CI: 1.27-3.24), when compared to normal-EA-BMI (18≤EA-BMI<25).
CONCLUSIONS: Two key modifiable behaviors, elevated BMI in early adulthood and heavy cumulative smoking history are independently associated with increased mortality risk in two North American cohorts of EAC patients.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Body mass index; Esophageal adenocarcinoma; Overall survival; Smoking

Mesh:

Year:  2017        PMID: 28088657     DOI: 10.1016/j.canep.2016.11.009

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  10 in total

1.  Nomogram predicting cancer-specific mortality in patients with esophageal adenocarcinoma: a competing risk analysis.

Authors:  Xi-Xi Wu; Ren-Pin Chen; Rui-Cong Chen; Hong-Peng Gong; Bin-Feng Wang; Ya-Ling Li; Xin-Ran Lin; Zhi-Ming Huang
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

2.  Bile acid and cigarette smoke enhance the aggressive phenotype of esophageal adenocarcinoma cells by downregulation of the mitochondrial uncoupling protein-2.

Authors:  Yuan Xu; Paul L Feingold; Deborah R Surman; Kate Brown; Sichuan Xi; Jeremy L Davis; Jonathan Hernandez; David S Schrump; R Taylor Ripley
Journal:  Oncotarget       Date:  2017-11-10

3.  Clinical significance of tumor necrosis factor receptor 2 in middle and lower thoracic esophageal squamous cell carcinoma.

Authors:  Dong Yang; Ruidong Li; Huili Wang; Junye Wang; Ye Li; Hongbo Wang; Wei Wang; Zifeng Liu
Journal:  Oncol Lett       Date:  2018-06-20       Impact factor: 2.967

4.  Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis.

Authors:  Fausto Petrelli; Alessio Cortellini; Alice Indini; Gianluca Tomasello; Michele Ghidini; Olga Nigro; Massimiliano Salati; Lorenzo Dottorini; Alessandro Iaculli; Antonio Varricchio; Valentina Rampulla; Sandro Barni; Mary Cabiddu; Antonio Bossi; Antonio Ghidini; Alberto Zaniboni
Journal:  JAMA Netw Open       Date:  2021-03-01

5.  Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium.

Authors:  Jessica L Petrick; Nan Li; Lesley A Anderson; Leslie Bernstein; Douglas A Corley; Hashem B El Serag; Sheetal Hardikar; Linda M Liao; Geoffrey Liu; Liam J Murray; Joel H Rubenstein; Jennifer L Schneider; Nicholas J Shaheen; Aaron P Thrift; Piet A van den Brandt; Thomas L Vaughan; David C Whiteman; Anna H Wu; Wei K Zhao; Marilie D Gammon; Michael B Cook
Journal:  Cancer       Date:  2019-09-06       Impact factor: 6.921

6.  Augmenting cancer registry data with health survey data with no cases in common: the relationship between pre-diagnosis health behaviour and post-diagnosis survival in oesophageal cancer.

Authors:  Paul P Fahey; Andrew Page; Glenn Stone; Thomas Astell-Burt
Journal:  BMC Cancer       Date:  2020-06-01       Impact factor: 4.430

7.  Prediagnostic adult body mass index change and esophageal adenocarcinoma survival.

Authors:  Elizabeth A Loehrer; Edward L Giovannucci; Rebecca A Betensky; Andrea Shafer; David C Christiani
Journal:  Cancer Med       Date:  2020-03-23       Impact factor: 4.452

8.  Using estimated probability of pre-diagnosis behavior as a predictor of cancer survival time: an example in esophageal cancer.

Authors:  Paul P Fahey; Andrew Page; Glenn Stone; Thomas Astell-Burt
Journal:  BMC Med Res Methodol       Date:  2020-04-03       Impact factor: 4.615

9.  Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study.

Authors:  R Stephen McCain; Damian T McManus; Stephen McQuaid; Jacqueline A James; Manuel Salto-Tellez; Nathan B Reid; Stephanie Craig; Chintapuza Chisambo; Victoria Bingham; Eamon McCarron; Eileen Parkes; Richard C Turkington; Helen G Coleman
Journal:  Cancer Causes Control       Date:  2019-11-30       Impact factor: 2.506

10.  Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China.

Authors:  Yutong He; Di Liang; Lingbin Du; Tiantian Guo; Yanyu Liu; Xibin Sun; Ning Wang; Min Zhang; Kuangrong Wei; Baoen Shan; Wanqing Chen
Journal:  Cancer Commun (Lond)       Date:  2020-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.